Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rate of severe cutaneous adverse reactions due to first-line anti-tuberculosis drugs
TCTR20180812003Not yet recruiting
- Sponsor
- Tipsiri Chaikong
- Start
- Sep 2018
- Countries
- 1
01
Overview
Trial in Tuberculosis (TB), sponsored by Tipsiri Chaikong. Primary endpoint: Rate of severe cutaneous adverse reactions. Planned start Sep 2018; status: not yet recruiting.
02
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on TCTR20180812003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20180812003.